AcelRx announces completion of human factors study for DSUVIA and plans to resubmit NDA
AcelRx Pharmaceuticals announced the successful completion of the human factors study performed to validate the effectiveness of the revised DSUVIA directions for use. This study was recommended by the FDA following the Company's application of FDA recommended changes to the DSUVIA DFU. April 16, 2018